global
outbreak
sever
acut
respiratori
syndrom
sar
pose
seriou
threat
public
health
signific
impact
socioeconom
stabil
although
global
outbreak
sar
contain
seriou
concern
reemerg
bioterror
potenti
date
specif
treatment
exist
diseas
review
progress
studi
pathogenesi
diseas
particular
studi
molecular
level
winter
new
plagu
emerg
guangdong
provinc
china
quickli
spread
countri
patient
character
fever
dri
cough
dyspnea
headach
hypoxemia
death
could
result
progress
respiratori
failur
due
alveolar
damag
syndrom
design
sever
acut
respiratori
syndrom
sar
identif
etiolog
agent
novel
coronaviru
sarsassoci
coronaviru
sarscov
quickli
made
intern
collabor
juli
pandem
termin
peopl
countri
diagnos
probabl
sar
die
http
wwwwhointcsrsarscountri
winter
sporad
case
report
includ
four
case
guangdong
provinc
laboratori
acquir
sar
singapor
taiwan
beij
http
wwwwhointcsrdon
archivediseasesevereacuterespiratorysyndromeenindex
html
although
death
rate
low
comparison
fatal
previou
pandem
rapid
spread
due
air
travel
coverag
media
enorm
econom
social
impact
fear
renew
outbreak
well
potenti
misus
viru
biolog
weapon
contribut
far
pronounc
impact
sarscov
sinc
identif
etiolog
agent
rapid
progress
made
toward
understand
newli
emerg
pathogen
previous
publish
review
focus
epidemiolog
clinic
present
potenti
treatment
sarscov
infect
review
focus
molecular
mechan
sar
pathogenesi
newli
identifi
viru
new
member
famili
coronavirida
genu
coronaviru
famili
larg
envelop
positivesens
singlestrand
rna
virus
replic
cytoplasm
anim
host
cell
genom
sarscov
kb
open
read
frame
orf
downstream
orf
encod
four
main
structur
protein
name
spike
envelop
e
membran
nucleocapsid
n
protein
spike
protein
sarscov
involv
viru
bind
fusion
entri
typic
class
viral
fusion
protein
similar
transmembran
glycoprotein
mani
envelop
virus
aminotermin
carboxyltermin
subunit
sarscov
protein
identifi
homolog
subunit
coronavirus
coronavirus
usual
subdivid
three
phylogenet
group
sarscov
differ
known
coronavirus
depend
method
sequenc
analysi
use
sarscov
either
constitut
new
phylogenet
group
subgroup
group
studi
use
pseudotyp
lentivirus
carri
e
glycoprotein
sarscov
demonstr
spike
protein
necessari
suffici
viru
attach
suscept
cell
cellular
receptor
detect
take
advantag
tag
vitro
studi
li
et
al
demonstr
angiotensinconvert
enzym
function
cellular
receptor
sarscov
use
coimmunoprecipit
viru
glycoprotein
lysat
cell
suscept
viru
infect
vero
cell
follow
mass
spectrometri
analysi
later
group
prove
crucial
sarscov
infect
vivo
employ
knockout
mous
later
structur
sar
coronaviru
spike
receptorbind
domain
rbd
complex
determin
find
influenc
ongo
vaccin
develop
biolog
analysi
immunostain
techniqu
identifi
surfac
type
type
alveolar
epitheli
cell
enterocyt
small
intestin
brush
border
proxim
tubular
cell
kidney
local
explain
document
tissu
tropism
sarscov
lung
gastrointestin
tract
howev
note
colon
enterocyt
well
liver
tissu
larg
neg
protein
express
sarscov
replic
occur
therein
contrast
wherea
strongli
express
endotheli
cell
arteri
vein
tissu
smooth
muscl
cell
intestin
tract
evid
viru
infect
site
observ
suggest
anoth
cellular
factor
requir
success
viru
infect
pseudotyp
viru
contain
spike
protein
also
shown
bind
dendrit
cellspecif
intercellular
adhes
molecul
nonintegrin
dcsign
dcsign
type
ii
transmembran
adhes
molecul
found
dendrit
cell
consist
tandem
repeat
highli
conserv
acid
sequenc
ctype
lectin
domain
recogn
carbohydr
residu
varieti
pathogen
unlik
receptor
pneumocyt
enterocyt
dcsign
permit
sarscov
infect
dendrit
cell
transfer
viru
suscept
target
cell
synapselik
structur
tran
infect
cellmedi
transfer
block
mous
antisarscov
spike
protein
antiserum
besid
dcsign
also
report
show
cell
express
molecul
ident
dcsign
lsign
enhanc
sarscov
infect
anoth
studi
prove
lsign
receptor
sarscov
express
clone
method
studi
also
indic
cell
express
lsign
becam
suscept
sarscov
infect
lsign
less
effici
receptor
compar
lsign
also
type
ii
transmembran
glycoprotein
ctype
lectin
famili
structur
similar
dcsign
except
lsign
consider
polymorph
tandem
repeat
domain
sinc
lsign
much
higher
polymorph
must
exist
differ
combin
popul
chan
et
al
found
homozyg
express
polymorph
variant
lsign
play
protect
role
sarscov
infect
cell
homozyg
lsign
show
higher
bind
capac
sarscov
higher
proteasomedepend
viral
degrad
low
capac
tran
infect
find
indic
lectin
may
play
role
pathogenehost
interact
whether
molecul
involv
sarscovehost
interact
remain
open
viru
attach
host
cell
viru
enter
cell
either
phdepend
receptormedi
endocytosi
direct
membran
fusion
current
consensu
question
sarscov
case
experi
demonstr
sarscov
might
gain
cell
entri
via
phdepend
endocytosi
also
studi
show
sar
coronaviru
enter
cell
direct
membran
fusion
ntermin
half
protein
contain
receptorbind
domain
wherea
ctermin
half
membraneanchor
membranefus
subunit
contain
two
heptad
repeat
region
nativ
state
spike
protein
viru
surfac
could
oligomer
form
form
stem
spike
sarscov
region
may
random
coil
conform
cover
domain
bind
target
cell
domain
chang
conform
form
ahelic
extend
insert
inert
fusion
peptid
target
cell
membran
expos
region
region
form
sixhelix
oligomer
complex
trimer
core
fusionact
core
structur
bring
viral
target
cell
membran
close
proxim
result
fusion
membran
format
fusion
pore
allow
viru
genom
enter
target
cell
apart
direct
membran
fusion
target
cell
surfac
sarscov
might
gain
cell
entri
via
phdepend
endocytosi
also
mediat
protein
spike
glycoprotein
envelop
rna
virus
mediat
attach
fusion
entri
viru
howev
activ
trigger
result
conform
chang
usual
requir
make
spike
glycoprotein
fulfil
function
exampl
bind
specif
receptorscoreceptor
activ
trigger
mlv
hiv
influenza
viru
requir
acid
milieu
howev
differ
case
sarscov
group
found
special
endosom
proteas
cathepsin
l
crucial
activ
viral
infect
inhibitor
cathepsin
l
prevent
sarscov
entri
sarscov
may
first
bind
cell
surfac
taken
vesicl
endocytosi
later
cleavag
spike
protein
cathepsin
l
facilit
fusion
viral
membran
vesicl
membran
result
consist
previou
find
show
inhibitor
vacuolar
acidif
could
block
infect
sbear
pseudotyp
dosedepend
manner
cathepsin
l
phdepend
cystein
proteas
maxim
activ
acid
milieu
may
lose
activ
increas
ph
therefor
spike
protein
mediat
entri
sarscov
might
direct
membran
fusion
phdepend
endocytosi
fashion
certain
factor
might
influenc
process
mean
incub
period
diseas
estim
day
ci
mean
time
onset
clinic
symptom
hospit
admiss
vari
day
common
symptom
includ
fever
chill
rigor
myalgia
cough
headach
also
report
patient
common
find
lymphopenia
thrombocytopenia
elev
lactat
dehydrogenas
creatin
kinas
level
wateri
diarrhea
also
report
result
autopsi
organ
show
predomin
damag
occur
lung
patholog
characterist
lung
includ
acut
pulmonari
exud
hemorrhag
inflamm
lung
tissu
greatli
increas
permeabl
capillari
lead
leakag
protein
cellulos
even
erythrocyt
alveolar
wall
space
accumul
exud
edema
fluid
alveoli
space
even
hyalin
membran
format
alveoli
space
airspac
opac
distribut
peripher
lower
lung
zone
commonli
encount
radiograph
imag
patient
sar
present
radiograph
progress
multifoc
bilater
lung
involv
follow
radiograph
improv
occur
treatment
patient
sar
cavit
lymphadenopathi
pleural
effus
demonstr
typic
sar
follow
threephas
clinic
cours
phase
viral
replic
phase
involv
initi
present
high
fever
myalgia
day
durat
gener
improv
day
increas
viral
load
phase
suggest
symptom
larg
relat
effect
viral
replic
cytolysi
howev
may
also
due
antivir
immunomodulatori
therapi
phase
begin
day
onset
fever
patient
frequent
recurr
fever
onset
diarrhea
oxygen
desatur
time
igg
seroconvers
start
day
seem
correl
fall
viral
load
occur
day
sever
clinic
worsen
also
occur
time
therefor
lung
damag
phase
like
relat
immunopatholog
damag
result
host
respons
rather
uncontrol
viral
replic
case
improv
steroid
treatment
enter
third
phase
rehabilit
deterior
evid
sever
lung
injuri
character
acut
respiratori
distress
syndrom
ard
necessit
ventil
epidemiolog
analysi
patient
popul
show
factor
may
influenc
final
outcom
diseas
firstli
age
patient
older
year
mortal
rate
exce
sar
children
especi
year
gener
associ
unev
cours
good
outcom
secondli
coexist
ill
especi
diabet
mellitu
heart
diseas
consist
found
independ
prognost
factor
poor
outcom
defin
death
need
mechan
ventil
admiss
intens
care
unit
thirdli
studi
increas
lactat
dehydrogenas
level
elev
neutrophil
count
time
admiss
well
low
lymphocyt
count
associ
poor
prognosi
although
much
learn
sar
three
year
sinc
discoveri
aspect
pathogenesi
diseas
still
fulli
understood
need
emphas
sinc
specif
drug
vaccin
avail
research
molecular
mechan
crucial
identifi
potenti
treatment
target
immunosuppress
condit
hiv
infect
treatment
immunosuppressor
less
sever
also
indic
immunopatholog
play
import
role
phase
use
steroid
sar
phase
seem
benefici
also
evid
inflamm
immun
respons
play
role
phase
gener
viral
infect
cell
type
bodi
respond
secret
high
level
type
interferon
case
sarscov
infect
immunerel
gene
overexpress
onset
sar
usual
associ
innat
immun
respons
bacteri
infect
viral
infect
exampl
express
lactoferrin
upregul
addit
innat
immun
defens
collectin
bind
glycosyl
sarscov
protein
may
play
import
role
host
defens
suggest
respons
sar
affect
patient
mainli
innat
inflammatori
respons
rather
specif
immun
respons
viral
infect
besid
function
limit
viru
spread
immunolog
respons
viral
infect
also
caus
patholog
damag
host
tissu
especi
concern
case
proinflammatori
cytokin
nichol
colleagu
suggest
proinflammatori
cytokin
releas
activ
macrophag
alveoli
could
promin
role
pathogenesi
sar
cell
essenti
adapt
immun
viral
infect
vivo
antivir
helper
cell
help
product
virusspecif
antibodi
b
cell
ctl
kill
virusinfect
host
cell
case
sarscov
infect
conclus
degre
cell
influenc
progress
diseas
sinc
lymphopenia
rapid
decreas
cell
common
acut
phase
sar
neutral
antibodi
igg
detect
sar
patient
suggest
humor
immun
play
import
role
elimin
viru
evidenc
activ
human
monoclon
antibodi
neutral
sarscov
infect
inhibit
syncytia
format
virusinduc
apoptosi
common
phenomenon
viral
infect
especi
rna
viru
infect
includ
coronavirus
apoptosi
use
host
cell
clear
viru
infect
cell
also
assist
viru
dissemin
releas
viral
particl
therebi
facilit
surviv
vivo
therefor
apoptosi
two
opposit
role
pathogen
viral
infect
enhanc
suppress
viral
infect
case
sar
apoptosi
observ
patient
lung
epitheli
cell
thu
sarscov
induc
apoptosi
would
certainli
deleteri
pathogen
role
lead
sever
tissu
damag
might
explain
sever
respiratori
system
damag
sar
patient
apoptosi
may
also
play
import
role
hematolog
chang
besid
direct
injuri
lung
mention
hematolog
chang
patient
sar
common
includ
lymphopenia
thrombocytopenia
occasion
leukopenia
mechan
underli
phenomenon
remain
unclear
studi
indic
apoptosi
well
immun
respons
involv
sever
studi
focus
mechan
sarscov
induc
apoptosi
exampl
proapoptot
compon
viru
gene
apoptosi
pathway
sarscov
infect
vero
cell
lead
apoptosi
studi
show
varieti
signal
pathway
phosphoryl
dephosphoryl
cell
infect
sarscov
specif
mitogenactiv
protein
kinas
mapk
thought
involv
induct
apoptosi
sinc
mizutani
et
al
found
mapk
downstream
target
activ
viral
replic
inhibitor
abl
partial
prevent
cytopath
effect
induc
sarscov
infect
signal
transduc
activ
transcript
stat
usual
constitut
phosphoryl
tyrosin
residu
dephosphoryl
sarscovinduc
activ
although
akt
inhibitor
apoptosi
also
partial
activ
weak
activ
prevent
sarscov
infectioninduc
apoptosi
vero
cell
recent
research
kda
ribosom
kinas
import
substrat
erk
show
specif
serin
residu
report
involv
autophosphoryl
activ
ctermin
kinas
domain
phosphoryl
confluent
sarscov
infect
cell
phosphoryl
inhibit
inhibitor
mapk
result
suggest
sarscov
induc
apoptosi
vero
cell
relat
mapk
besid
whole
viru
certain
compon
viru
also
induc
apoptosi
report
sarscov
protein
induc
apoptosi
sar
coronaviru
nucleocapsid
protein
induc
apoptosi
cell
absenc
growth
factor
ctermin
domain
sarscov
spike
protein
suffici
induc
apoptosi
vero
cell
recent
studi
show
induct
apoptosi
protein
also
relat
abil
activ
mapk
adult
sar
patient
respiratori
distress
princip
caus
mortal
histolog
chang
associ
ard
call
diffus
alveolar
damag
dad
character
structureless
noncellular
exud
fill
bronchiol
dad
associ
high
mortal
rate
apart
support
clinic
care
specif
therapeut
option
proven
benefit
recent
studi
shown
reninangiotensin
system
play
import
role
sarscov
caus
acut
lung
failur
acid
aspir
sepsi
wildtyp
mice
mimic
human
acut
lung
injuri
result
impair
lung
function
assess
lung
elast
blood
oxygen
pulmonari
edema
mice
develop
edema
alveolar
wall
thicken
bleed
inflammatori
cell
infiltr
hyalin
membran
format
knockout
mice
lung
injuri
much
sever
wildtyp
mice
assess
similarli
rescu
experi
use
recombin
human
protein
show
decreas
degre
acut
lung
injuri
knockout
wildtyp
mice
result
demonstr
loss
essenti
lung
injuri
ace
key
enzym
reninangiotensin
system
ace
cleav
decapeptid
angiotensini
angi
octapeptid
angiotensinii
angii
cleav
singl
residu
angi
gener
residu
angii
gener
way
counterbal
function
ace
neg
regul
angii
level
thu
loss
express
lead
high
level
angii
receptor
caus
role
acut
lung
failur
fig
specul
acut
lung
failur
caus
sarscov
mainli
due
function
first
found
experiment
infect
sarscov
wildtyp
mice
result
consider
reduc
express
lung
ace
express
chang
test
hypothesi
establish
defin
model
system
use
recombin
sarscov
spike
protein
model
system
allow
us
avoid
possibl
secondari
effect
result
viral
replic
infect
vivo
directli
test
whether
sarscov
spike
protein
might
advers
affect
acut
lung
injuri
modul
system
found
bind
spike
endogen
vero
cell
also
result
downregul
surfac
express
studi
show
treatment
spike
protein
worsen
lung
function
wildtyp
mice
moreov
spike
treatment
acidchalleng
wildtyp
mice
augment
patholog
chang
lung
parenchyma
increas
lung
edema
vivo
spike
protein
administr
affect
sever
lung
failur
knockout
mice
indic
effect
spike
protein
acut
lung
injuri
specif
thu
hypothes
infect
sarscov
result
downregul
bind
sarscov
spike
protein
given
key
neg
regulatori
factor
sever
lung
edema
acut
lung
failur
sarscov
spike
proteinmedi
downregul
contribut
sever
lung
patholog
fig
one
million
peopl
suffer
ard
due
differ
dispos
factor
death
rate
reach
recombin
angiotensin
ii
receptor
inhibitor
alreadi
clinic
use
control
blood
pressur
find
point
possibl
therapi
otherwis
incur
diseas
fig
besid
ard
contribut
significantli
sarscov
caus
death
sarscov
associ
diseas
hypertens
glucos
increas
heart
dysfunct
ignor
mechan
underli
pathogenesi
still
unclear
need
understood
current
antivir
therapi
proven
valu
sar
clinic
treatment
sar
includ
antisarscov
therapi
antiinflammatori
treatment
limit
viral
pneumon
subsequ
pulmonari
fibrosi
insight
field
sar
pathogenesi
sarscov
genom
structur
novel
potenti
therapeut
target
antivir
therapi
evalu
exampl
inhibitor
step
viru
life
cycl
like
bind
inhibitor
fusion
inhibitor
rna
transcript
replic
inhibitor
well
proteas
inhibitor
design
evalu
potenti
antisar
agent
test
anim
model
efficaci
human
still
unknown
inconsist
result
differ
group
investig
compound
may
relat
test
methodolog
particular
differ
vitro
vivo
antivir
mechan
new
technolog
sirna
may
import
howev
new
technolog
still
riddl
practic
difficulti
like
efficaci
deliveri
system
safeti
concern
limit
applic
patient
treatment
use
sera
peopl
convalesc
sar
treat
sar
patient
prove
effect
impli
neutral
antibodi
serv
therapeut
strategi
retrospect
studi
limit
number
patient
use
human
sar
convalesc
plasma
suggest
passiv
immun
obviou
advers
effect
howev
use
convalesc
sera
practic
therapi
especi
outbreak
worldwid
still
effect
antivir
therapi
use
immedi
patient
promis
method
prevent
diseas
protect
vaccin
immedi
sar
outbreak
research
began
investig
whether
inactiv
vaccin
could
use
prevent
sar
china
collabor
group
chines
academi
medic
scienc
china
cdc
sinovac
biotech
compani
pass
inactiv
sarscov
strain
vaccin
clinic
trial
phase
sfda
summer
although
inactiv
sar
vaccin
seem
use
reason
sar
prevent
safeti
inactiv
sarscov
vaccin
seriou
concern
vaccin
target
structur
gene
especi
recombin
spike
protein
seem
safest
strategi
dna
vaccin
encod
protein
elicit
neutral
antibodi
induc
cell
respons
protect
mice
sar
infect
varieti
vector
use
express
spike
protein
use
immun
mice
african
green
monkey
hamster
neutral
antibodi
detect
protect
infect
dna
sar
vaccin
invent
scientist
nation
institut
allergi
infecti
diseas
produc
vical
inc
san
diego
enter
clinic
trial
phase
us
fda
guidelin
end
recent
group
prove
rbd
could
elicit
much
higher
titer
neutral
antibodi
fulllength
protein
suggest
rbd
may
potenti
vaccin
candid
howev
discoveri
spike
rbd
alon
could
worsen
acut
lung
injuri
mice
indic
potenti
safeti
issu
spike
protein
vaccin
harm
spike
rbd
lung
thought
caus
bind
sar
receptor
report
protein
sar
outbreak
much
less
sever
outbreak
differ
bind
affin
receptor
latter
lower
affin
human
mainli
due
alter
amino
acid
residu
site
therefor
order
obtain
safer
recombin
spike
protein
vaccin
sitedirect
mutagenesi
site
might
necessari
elimin
bind
affin
spike
summari
global
outbreak
sar
led
format
success
network
laboratori
much
learn
sar
three
year
sinc
discoveri
howev
aspect
molecular
pathogenesi
diseas
still
fulli
understood
investig
variou
aspect
includ
life
cycl
viru
molecular
mechan
diseas
factor
influenc
progress
diseas
result
thorough
understand
new
pathogen
result
research
certainli
suggest
promis
treatment
strategi
may
lead
prevent
diseas
fig
schemat
represent
role
ra
sarscov
induc
acut
lung
injuri
potenti
therapeut
drug
ace
cleav
angiotensin
produc
angiotensin
ii
either
bind
lead
lung
injuri
bind
reduc
sever
lung
injuri
contrari
counteract
ace
convert
angiotensin
ii
less
damag
molecul
sarscov
infect
spike
protein
treatment
downregul
express
thu
aggrav
lung
injuri
base
find
ace
inhibitor
lisinopri
captopri
inhibitor
losartan
valsartan
well
recombin
human
potenti
drug
kind
acut
lung
injuri
